S 526

Provides that purchase of insulin is not subject to deductible; requires health insurers to limit copayments and coinsurance for insulin; requires insulin manufacturers to submit report to Commissioner of Banking and Insurance

S526 (Vitale, Pou, Sweeney) Insulin costs have risen dramatically over the past decade, and many individuals in need of insulin find it difficult to pay for the cost of this needed drug. This bill would limit the copay for insulin to $50 for a 30-day supply and require that purchases of insulin not be subject to any deductibles. This will help those who need insulin to afford it. NJEA also suggests that the legislature also look at other solutions to address the underlying cost of insulin.

NJEA supports  S 526.